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Background
Synaptic dysfunction is widely thought to be an important
pathogenic event in Alzheimer’s disease (AD). Presenilins,
which harbor large numbers of mutations for familial AD
and frontotemporal dementia (FTD), are important for
neurotransmitter release and synaptic plasticity as well as
memory and age-related neuronal survival.
Results
Our recent report showed that presenilins regulate synap-
tic function by modulating ryanodine receptor-mediated
calcium release from the ER. To determine how preseni-
lins regulate intracellular calcium signaling in neurons, we
performed Ca
2+ imaging coupled with electrophysiological
and molecular analyses using both acute hippocampal
slices of unique presenilin conditional mutant mice and
cultured hippocampal neurons, in which presenilins are
acutely inactivated with a lentivirus expressing Cre
recombinase.
Conclusion
Our results reveal a selective interaction between preseni-
lins and ryanodine receptors in the regulation of calcium
homeostasis and synaptic function, and suggest that dis-
ruption of calcium homeostasis may be an early patho-
genic event leading to synaptic dysfunction in AD. We
also generated two presenilin-1 knockin mice, in which
either an AD- (L435F) or FTD (G183V) -causing mutation
is introduced into the respective presenilin-1 endogenous
genomic locus, to investigate the mechanisms by which
presenilin mutations cause AD or FTD. The analysis of
these mutant mice will also be presented.
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